On July 13, 2016, the Arthritis Advisory Committee (AAC) supported by a vote of 20-Yes to 0-No, with no abstentions, that the totality of the evidence supports licensure of GP2015, a proposed biosimilar to Amgen Inc.’s Enbrel (etanercept), submitted by Sandoz, Inc. (Sandoz), a unit of Novartis AG.
Back to All Events
Earlier Event: July 12
Arthritis Advisory Committee
Later Event: July 19
Dermatologic and Opthalmic Drugs Advisory Committee